Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab During Hospitalisation for Severe Eosinophilic COPD Exacerbations
2018-003924-35Phase 2Unknown
- Sponsor
- University of Leicester
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic obstructive pulmonary disease (COPD) comparing Mepolizumab arm with Placebo arm (2 arms). Primary endpoint: Time to next hospital readmission or all-cause death. Status: unknown.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2018-003924-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003924-35.